Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.50 |
| ▸ | FNTB | P49356 | 15/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759220 | 0.81 | MEN1 (0.38) | FNTAFNTBMEN1KMT2A | |
| SCHEMBL6760847 | 0.81 | FNTA (0.53) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL6759200 | 0.80 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL7255297 | 0.79 | FNTA (0.52) | FNTAFNTBPGGT1B | |
| SCHEMBL6759221 | 0.76 | MEN1 (0.39) | FNTAFNTBMEN1KMT2A | |
| SCHEMBL8608376 | 0.72 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL6754945 | 0.72 | KMT2A (0.66) | FNTAFNTBMEN1KMT2A | |
| SCHEMBL6754940 | 0.72 | KMT2A (0.66) | FNTAFNTBMEN1KMT2A | |
| SCHEMBL5156271 | 0.68 | CA1 (0.43) | MEN1KMT2A | |
| SCHEMBL5152108 | 0.65 | CA1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | PIERRE FABRE MEDICAMENT (FR) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | CBR1, CBR3, HCCS | FNTA 338/4885FNTB 215/4885PGGT1B 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.